Altered sulfide (H2S) metabolism in ethylmalonic encephalopathy

Cold Spring Harbor Perspectives in Biology

Volumn 5, Issue 1, 2013, Pages

  Tiranti, Valeria ^a   Zeviani, Massimo ^a  

^a DEPARTMENT OF NEUROSURGERY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84872029094     PISSN: None     EISSN: 19430264     Source Type: Journal    
DOI: 10.1101/cshperspect.a011437     Document Type: Review

References (72)

1. Abe K, Kimura H. 1996. The possible role of hydrogen sulfide as an endogenous neuromodulator. J Neurosci 16: 1066-71.
2. Ali MY, Ping CY, Mok YY, Ling L, Whiteman M, Bhatia M, Moore PK. 2006. Regulation of vascular nitric oxide in vitro and in vivo; a new role for endogenous hydrogen sulphide? Br J Pharmacol 149: 625-34.
3. Atkuri KR, Mantovani JJ, Herzenberg LA, Herzenberg LA. 2007. N-Acetylcysteine-a safe antidote for cysteine/glutathione deficiency. Curr Opin Pharmacol 7: 355-359.
4. Awata S, Nakayama K, Suzuki I, Sugahara K, Kodama H. 1995. Changes in cystathionine g-lyase in various regions of rat brain during development. Biochem Mol Biol Int 35: 1331-1338.
5. Beauchamp RO Jr, Bus JS, Popp JA, Boreiko CJ, Andjelkovich DA. 1984. A critical review of the literature on hydrogen sulfide toxicity. Crit Rev Toxicol 13: 25-97.
6. Burlina A, Zacchello F, Dionisi-Vici C, Bertini E, Sabetta G, Bennet MJ, Hale DE, Schmidt-Sommerfeld E, Rinaldo P. 1991. New clinical phenotype of branched-chain acyl-CoA oxidation defect. Lancet 338: 1522-1523.
7. Buzaleh AM, Vazquez ES, del Carmen Battle AM. 1990. Cyanide intoxication-III: On the analogous and different effects provoked by non-lethal and lethal challenged doses. Gen Pharmacol 21: 27-32.
8. Cai WJ, Wang MJ, Moore PK, Jin HM, Yao T, Zhu YC. 2007. The novel proangiogenic effect of hydrogen sulfide is dependent on Akt phosphorylation. Cardiovasc Res 76: 29-40.
9. Coleman JE. 1967. Mechanism of action of carbonic anhydrase: Subtrate, sulfonamide, and anion binding. J Biol Chem 242: 5212-5219.
10. Cooper AJ, Bruschi SA, Iriarte A, Martinez-Carrion M. 2002. Mitochondrial aspartate aminotransferase catalyses cysteine S-conjugate b-lyase reactions. Biochem J 368: 253-261.
11. Di Meo I, Fagiolari G, Prelle A, Viscomi C, Zeviani M, Tiranti V. 2011. Chronic exposure to sulfide causes accelerated degradation of cytochrome c oxidase in ethylmalonic encephalopathy. Antioxid Redox Signal 15: 353-362.
12. Di Meo I, Auricchio A, Lamperti C, Burlina A, Viscomi C, Zeviani M. 2012. Effective AAV-mediated gene therapy in a mouse model of ethylmalonic encephalopathy. EMBO Mol Med 4: 1008-1014.
13. Di RoccoDi Rocco M, Caruso U, Briem E, Rossi A, Allegri AE, Buzzi D, Tiranti V. 2006. A case of ethylmalonic encephalopathy with atypical clinical and biochemical presentation. Mol Genet Metab 89: 395-397.
14. Diwakar L, Ravindranath V. 2007. Inhibition of cystathionine g-lyase leads to loss of glutathione and aggravation of mitochondrial dysfunction mediated by excitatory amino acid in the CNS. Neurochem Int 50: 418-426.
15. Eisenstein BI, Schaechter M. 2007. DNA and chromosome mechanics. In Schaechter's mechanisms of microbial disease (ed. Engleberg NC, et al.), p. 28. LippincottWilliams & Wilkins: Hagerstown, MD. Elrod JW, Calvert JW, Morrison J, Doeller JE, Kraus DW
16. Elrod JW, Calvert JW, Morrison J, Doeller JE, Kraus DW, Tao L, Jiao X, Scalia R, Kiss L, Szabo C, et al. 2007. Hydrogen sulfide attenuates myocardial ischemia-reperfusion injury by preservation of mitochondrial function. Proc Natl Acad Sci 104: 15560-15565.
17. 2S). Cell Biochem Funct 28: 95-106.
18. Enokido Y, Suzuki E, Iwasawa K, Namekata K, Okazawa H, Kimura H. 2005. Cystathionine b-synthase, a key enzyme for homocysteine metabolism, is preferentially expressed in the radial glia/astrocyte lineage of developing mouse CNS. FASEB J 19: 1854-1856.
19. Feng C, Tollin G, Enemark JH. 2007. Sulfite oxidizing enzymes. Biochim Biophys Acta 1774: 527-539.
20. Ferdinandy P, Schulz R, Baxter GF. 2007. Interaction of cardiovascular risk factors with myocardial ischemia/reperfusion injury, preconditioning, and postconditioning. Pharmacol Rev 59: 418-458.
21. Fiorucci S, Distrutti E, Cirino G, Wallace JL. 2006. The emerging roles of hydrogen sulfide in the gastrointestinal tract and liver. Gastroenterology 131: 259-271.
22. Furne J, Saeed A, Levitt MD. 2008. Whole tissue hydrogen sulfide concentrations are orders of magnitude lower than presently accepted values. Am J Physiol Regul Integr Comp Physiol 295: R1479-R1485.
23. Goodwin LR, Francom D, Dieken FP, Taylor JD, WarenyciaMW. 1989. Determination of sulfide in brain tissue by gas dialysis/ion chromatography: Postmortem studies and two case reports. J Anal Toxicol 13: 105-109.
24. Gregersen N, Andresen BS, Bross P. 2000. Prevalent mutations in fatty acid oxidation disorders: diagnostic considerations. Eur J Pediatr 159: S213-S218.
25. Halter J, Schüpbach WM, Casali C, Elhasid R, Fay K, Hammans S, Illa I, Kappeler L, Krähenbühl S, LehmannT, et al. 2011. Allogeneic hematopoietic SCT as treatment option for patients with mitochondrial neurogastrointestinal encephalomyopathy (MNGIE): Aconsensus conference proposal for a standardized approach. Bone Marrow Transplant 46: 330-337.
26. Hildebrandt TM. 2011. Modulation of sulfide oxidation and toxicity in rat mitochondria by dehydroascorbic acid. Biochim Biophys Acta 1807: 1206-1213.
27. Hildebrandt TM, Grieshaber MK. 2008. Three enzymatic activities catalyze the oxidation of sulfide to thiosulfate in mammalian and invertebrate mitochondria. FEBS J 275: 3352-3361.
28. Hill BC, Woon TC, Nicholls P, Peterson J, Greenwood C, Thomson AJ. 1984. Interactions of sulphide and other ligands with cytochrome c oxidase. An electron-paramagnetic-resonance study. Biochem J 224: 591-600.
29. Holdorf MM, Bennett B, CrowderMW, Makaroff CA. 2008. Spectroscopic studies on Arabidopsis ETHE1, a glyoxalase II-like protein. J Inorg Biochem 102: 1825-1830.
30. Hosoki R, Matsuki N, Kimura H. 1997. The possible role of hydrogen sulfide as an endogenous smooth muscle relaxant in synergy with nitric oxide. Biochem Biophys Res Commun 237: 527-531.
31. Ishii I, Akahoshi N, Yu XN, Kobayashi Y, Namekata K, Komaki G, Kimura H. 2004. Murine cystathionine g-lyase: Complete cDNA and genomic sequences, promoter activity, tissue distribution and developmental expression. Biochem J 381: 113-123.
32. Jackson MR, Melideo SL, Jorns MS. 2012. Human sulfide: Quinone oxidoreductase catalyzes the first step in hydrogen sulfide metabolism and produces a sulfane sulfur metabolite. Biochemistry 51: 6804-6815.
33. Kang SS, Bloom SM, Norian LA, Geske MJ, Flavell RA, Stappenbeck TS, Allen PM. 2008. An antibiotic-responsive mouse model of fulminant ulcerative colitis. PLoS Med 4: 5.
34. Kimura Y, Kimura H. 2004. Hydrogen sulfide protects neurons from oxidative stress. FASEB J 18: 1165-1167.
35. 2receptors. Respir Physiol 32: 355-367.
36. Korman SH, Inborn errors of isoleucine degradation: A review. 2006. Mol Genet Metab 89: 289-99.
37. Mari{dotless}́ M, Morales A, Colell A, Garci{dotless}́a-Ruiz C, Fernández-Checa JC. 2009. Mitochondrial glutathione, a key survival antioxidant. Antioxid Redox Signal 11: 2685-2700.
38. Merinero B, Pérez-Cerdá C, Ruiz Sala P, Ferrer I, Garci{dotless}́a MJ, Marti{dotless}́nez Pardo M, Belanger-Quintana A, de la Mota JL, Martin-Hernández E, Vianey-Saban C, et al. 2006. Persistent increase of plasma butyryl/isobutyrylcarnitine concentrations as marker of SCAD defect and ethylmalonic encephalopathy. J Inherit Metab Di 29: 685.
39. Mineri R, Rimoldi M, Burlina AB, Koskull S, Perletti C, Heese B, von Döbeln U, Mereghetti P, Di Meo I, Invernizzi F, et al. 2008. Identification of new mutations in the ETHE1 gene in a cohort of 14 patients presenting with ethylmalonic encephalopathy. J Med Genet 45: 473-478.
40. Mitchell TW, Savage JC, Gould DH. 1993. High-performance liquid chromatography detection of sulfide in tissues from sulfide-treated mice. J Appl Toxicol 13: 389-394.
41. Müller FH, Bandeiras TM, Urich T, Teixeira M, Gomes CM, Kletzin A. 2004. Coupling of the pathway of sulphur oxidation to dioxygen reduction: Characterization of a novel membrane-bound thiosulphate:quinone oxidoreductase. Mol Microbiol 53: 1147-1160.
42. Nowaczyk MJ, Lehotay DC, Platt BA, Fisher L, Tan R, Phillips H, Clarke JT. 1998. Ethylmalonic and methylsuccinic aciduria in ethylmalonic encephalopathy arise from abnormal isoleucine metabolism. Metabolism 47: 836-839.
43. Ogasawara Y, Isoda S, Tanabe S. 1994. Tissue and subcellular distribution of bound and acid-labile sulfur, and the enzymic capacity for sulfide production in the rat. Biol Pharm Bull 17: 1535-1542.
44. Oh GS, PaeHO, Lee BS, Kim BN, Kim JM, Kim HR, Jeon SB, Jeon WK, Chae HJ, Chung HT. 2006. Hydrogen sulfide inhibits nitric oxide production and nuclear factor-kB via heme oxygenase-1 expression in RAW2647 macrophages stimulated with lipopolysaccharide. Free Radic Biol Med 41: 106-119.
45. Palmfeldt J, Vang S, Stenbroen V, Pavlou E, Baycheva M, Buchal G, Monavari AA, Augoustides-Savvopoulou P, Mandel H, Gregersen N. 2011. Proteomics reveals that redox regulation is disrupted in patients with ethylmalonic encephalopathy. J Proteome Res 10: 2389-2396.
46. Pedersen CB, Bross P, Winter VS, Corydon TJ, Bolund L, Bartlett K, Vockley J, Gregersen N. 2003. Misfolding, degradation, and aggregation of variant proteins. The molecular pathogenesis of short chain acyl-CoA dehydrogenase (SCAD) deficiency. J Biol Chem 278: 47449-47458.
47. Powell MA, Somero GN. 1986. Hydrogen sulfide oxidation is coupled to oxidative phosphorylation in mitochondria of Solemya reidi. Science 233: 563-566.
48. Qingyou Z, Junbao D, Weijin Z, Hui Y, Chaoshu T, Chunyu Z. 2004. Impact of hydrogen sulfide on carbon monoxide/ heme oxygenase pathway in the pathogenesis of hypoxic pulmonary hypertension. Biochem Biophys Res Commun 317: 30-37.
49. Reiffenstein RJ, Hulbert WC, Roth SH. 1992. Toxicology of hydrogen sulfide. Annu Rev Pharmacol Toxicol 32: 109-134.
50. Rowan FE, Docherty NG, Coffey JC, O'Connell PR. 2009. Sulphate-reducing bacteria and hydrogen sulphide in the aetiology of ulcerative colitis. Br J Surg 96: 151-158.
51. Searcy DG, Lee SH. 1998. Sulfur reduction by human erythrocytes. J Exp Zool 282: 310-322.
52. Samuelson J. 1999. Why metronidazole is active against both bacteria and parasites. Antimicrob Agents Chemother 43: 1533-1541.
53. Stipanuk MH. 2004. Role of the liver in regulation of body cysteine taurine levels: A brief review. Neurochem Res 29: 105-110.
54. Stipanuk MH, Beck PW. 1982. Characterization of the enzymic capacity for cysteine desulphhydration in liver and kidney of the rat. Biochem J 206: 267-277.
55. Stipanuk MH, Ueki I. 2010. Dealing with methionine/homocysteine sulfur: Cysteine metabolism to taurine and inorganic sulfur. J Inherit Metab Dis 34: 17-32.
56. Szabó C. 2007. Hydrogen sulphide and its therapeutic potential. Nat Rev Drug Discov 6: 917-935.
57. Theissen U, MartinW. 2008. Sulfide: quinone oxidoreductase (SQR) from the lugworm Arenicola marina shows cyanide-and thioredoxin-dependent activity. FEBS J 275: 1131-1139.
58. Tiranti V, D'Adamo P, Briem E, Ferrari G, Mineri R, Lamantea E, Mandel H, Balestri P, Garcia-Silva MT, Vollmer B, et al. 2004. Ethylmalonic encephalopathy is caused by mutations in ETHE1, a gene encoding a mitochondrial matrix protein. Am J Hum Genet 74: 239-252.
59. Tiranti V, Briem E, Lamantea E, Mineri R, Papaleo E, De Gioia L, Forlani F, Rinaldo P, Dickson P, Abu-Libdeh B, et al. 2006. ETHE1 mutations are specific to ethylmalonic encephalopathy. J Med Genet 43: 340-346.
60. Tiranti V, Viscomi C, Hildebrandt T, Di Meo I, Mineri R, Tiveron C, LevittMD, Prelle A, Fagiolari G, Rimoldi M, et al. 2009. Loss of ETHE1, a mitochondrial dioxygenase, causes fatal sulfide toxicity in ethylmalonic encephalopathy. Nat Med 15: 200-205.
61. Viscomi C, Burlina AB, Dweikat I, Savoiardo M, Lamperti C, Hildebrandt T, Tiranti V, Zeviani M. 2010. Combined treatmentwith oral metronidazole andN-acetylcysteine is effective in ethylmalonic encephalopathy. Nat Med 16: 869-871.
62. 2S be the third endogenous gaseous transmitter? FASEB J 16: 1792-1798.
63. Westley AM, Westley J. 1991. Biological sulfane sulfur. Biochemistry 195: 63-67.
64. Whiteman M, Armstrong JS, Chu SH, Jia-Ling S, Wong BS, Cheung NS, Halliwell B, Moore PK. 2004. The novel neuromodulator hydrogen sulfide: An endogenous peroxynitrite "scavenger?" J Neurochem 90: 765-768.
65. Whiteman M, Li L, Kostetski I, Chu SH, Siau JL, Bhatia M, Moore PK. 2006. Evidence for the formation of a novel nitrosothiol from the gaseous mediators nitric oxide and hydrogen sulphide. Biochem Biophys Res Commun 343: 303-310.
66. Xu M, Wu YM, Li Q, Wang X, He RR. 2008. Electrophysiological effects of hydrogen sulfide on pacemaker cells in sinoatrial nodes of rabbits. Sheng LiXue Bao 60: 175-180.
67. Yalamanchili C, Smith MD. 2008. Acute hydrogen sulfide toxicity due to sewer gas exposure. Am J Emerg Med 26: 518. e5-7.
68. Yan SK, Chang T, Wang H, Wu L, Wang R, Meng QH. 2006. Effects of hydrogen sulfide on homocysteine-induced oxidative stress in vascular smooth muscle cells. Biochem Biophys Res Commun 361: 485-491.
69. Yang G, Sun X, Wang R. 2004. Hydrogen sulfide-induced apoptosis of human aorta smooth muscle cells via the activation of mitogen-activated protein kinases and caspase-3. FASEB J 18: 1782-1784.
70. 2S as a physiologic vasorelaxant: hypertension in mice with deletion of cystathionine g-lyase. Science 322: 587-590.
71. Zafeiriou DI, Augoustides-Savvopoulou P, Haas D, Smet J, Triantafyllou P, Vargiami E, Tamiolaki M, Gombakis N, van Coster R, Sewell AC, et al. 2007. Ethylmalonic encephalopathy: Clinical and biochemical observations. Neuropediatrics 38: 78-82.
72. 2S as a novel endogenous gaseous KATP channel opener. EMBO J 20: 6008-6016.